Serum transferrin and ceruloplasmin in patients with cancer of the gastrointestinal and other systems.
Serum transferrin and ceruloplasmin were determined in 20 healthy subjects, 23 patients with cancer of the gastro-intestinal system (G.I.S) and 22 patients with other types of cancer. Serum transferrin in patients with cancer of the G.I.S. was significantly decreased in comparison to that of healthy subjects (p < 0.05) and to that of other cancer patients (p < 0.005), but no significant difference was found between the values of healthy subjects and those with other types of cancer. Serum ceruloplasmin was significantly increased in patients with cancer of the G.I.S. (p < 0.01) and other types (p < 0.05) in comparison to that of healthy subjects. No significant difference was found between patients with cancer of the G.I.S. and those with other cancer types. In conclusion, transferrin was significantly decreased in the serum of patients with cancer of the G.I.S. while ceruloplasmin was significantly increased in both groups of patients with G.I.S. and other types of cancer.
Agroyannis
B
B
Aretaieon University Hospital of Athens, Greece.
Dalamangas
A
A
Dardouphas
K
K
Fortoynas
C
C
Saloum
G
G
Stringou
E
E
Tzanatos
H
H
Koutsikos
D
D
Papadimitriou
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002570:Ceruloplasmin / Q000378:metabolism*; D005770:Gastrointestinal Neoplasms / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D014168:Transferrin / Q000378:metabolism*
D014168:Transferrin; D002570:Ceruloplasmin